Agreement demonstrates growing use of OncoDNA solutions across Europe
- Agreement demonstrates growing use of OncoDNA solutions across Europe
Gosselies, Belgium – October 22, 2018: OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, announces today an agreement with Gammaray Private Health Services to distribute OncoDNA’s comprehensive molecular profiling products in Turkey and with AMS 2000 Trading Impex for Romania.
Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: “This agreement with Gammaray and AMS confirms the growing interest of OncoDNA’s comprehensive molecular profiling solutions in Turkey and Romania. With these exciting and exclusive partnerships we anticipate a strong increase in the use of OncoDNA profiling products in the Europe.”
Dr Cengiz Gemici, Chief Executive Officer of Gammaray, said: “This agreement between Gammaray and OncoDNA is a new phase in cancer diagnostics for Turkish cancer patients. With OncoDNA’s innovative comprehensive molecular and genomic testing platforms, patients benefit from the most suitable and effective treatment options available to them, while exposure to potentially ineffective therapies are reduced under the guidance of useful precision medicine reporting services such as OncoSHARE. This is an exciting opportunity for both companies to make a significant improvement to the oncology environment in Turkey.”
Radu Crijanovschi Chief Executive Officer of AMS 200 Trading Impex, said: “We are very delighted to start collaboration with OncoDNA. Together we will be able to help oncologists and patients in Romania to benefit and access the most comprehensive genetic testing in oncology treatment.”
About Gammaray Private Health Services
The Gammaray Private Health Services is a 30-year-old multi-tasked oncological approach that operates in medical oncology, radiation oncology and radiology specialties in private hospitals which are owned by medical and radiation oncologists providing a wide range of comprehensive treatment options for different oncological problems. These services are delivered via 4 different regions of Istanbul city throughout Turkey. The hospitals are equipped with Elekta which the radiation oncology partner brand of Gammaray Private Health Services is
At the beginning of 2018, Gammaray decided to enter the diagnostics market with liquid biopsy/tissue biopsy/gene signature brands and enlarge its product portfolio while aiming to be the first in the minds of oncology clinicians through years of experience in the genetic profiling market. Gammaray Private Health Services welcomes OncoDNA test brands which are best in class diagnostics to its portfolio as a healthcare provider and is very enthusiastic about potential benefits to patients from these broad range NGS+IHC profiling tools.
About AMS 2000 Trading Impex
AMS 2000 Trading Impex was founded in 1997 and today is one of the most reliable, experienced and well-known company’s in medical laboratory diagnostics distribution in Romania.
In 2007 the company became member of BATM Advanced Communications Group of companies.
Our main goal is to deliver best practices in a predictable and reliable service manner that fulfills our partners’ needs in every aspect. We aim to do so by representing a modern product portfolio and professional expertise and by means of our strong and reliable service background.
AMS 2000 Trading Impex HQ, respectively the main office and the warehouse, are located in Bucharest. Additionally, there are three regional offices, one in the Western part of the country (Timisoara), one in the Central part (Cluj) and the other one in the Eastern part (Iasi). Thus, AMS covers the complete territory of Romania and has 70 employees.
We don’t just sell products, we provide comprehensive solutions for any Laboratory and Medical Institution.
About OncoDNA
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ that continuously ‘learns’ from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to an individual patient’s cancer profile. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, and employs c.55 employees in four countries.
For more information please visit www.oncodna.com
Contact
| OncoDNA | +32 (0) 71 18 35 00 |
| Jean-Pol Detiffe, CEO | |
| Consilium Strategic Communications | +44 (0)20 3709 5700 |
| Amber Fennell, Jonathan Birt, Sukaina Virji, Nicholas Brown, Hendrik Thys | oncodna@consilium-comms.com |
